Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.73 |
| ▸ | CCR3 | P51677 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24762108 | 0.94 | SIGMAR1 (0.68) | SIGMAR1CCR3KCNH2MEN1TP53 | |
| SCHEMBL12424500 | 0.87 | CCR3 (0.73) | CCR3CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL8091672 | 0.86 | SIGMAR1 (0.97) | SIGMAR1CCR3KCNH2MEN1TP53 | |
| SCHEMBL12041264 | 0.86 | KCNH2 (0.81) | SIGMAR1CCR3KCNH2HRH3 | |
| SCHEMBL7444256 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CCR3KCNH2MEN1TP53 | |
| SCHEMBL7374609 | 0.84 | SIGMAR1 (1.00) | SIGMAR1CCR3KCNH2MEN1TP53 | |
| SCHEMBL7444410 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CCR3KCNH2MEN1TP53 | |
| SCHEMBL7437079 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CCR3KCNH2MEN1TP53 | |
| SCHEMBL7446629 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CCR3KCNH2MEN1TP53 | |
| SCHEMBL7449513 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CCR3KCNH2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | SIGMAR1 4049/4885CCR3 2850/4885KCNH2 969/4885 |
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | MPO, DHODH, DHX35 | SIGMAR1 4211/4885CCR3 684/4885KCNH2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.